EVT Evotec SE

Novo A/S Becomes New Long-Term Strategic Shareholder in Evotec

Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it resolved on a capital increase from its authorised capital against cash. Evotec will issue 13,146,019 new shares to Novo A/S (Denmark). Novo A/S is the independent holding company for the Novo Group.

In this private capital increase, Novo A/S will invest EUR 90.3 m to subscribe shares of Evotec at a share price of EUR 6.87 per share. The placement was made at a zero discount to the XETRA closing auction price of the Evotec stock on 09 February 2017. With the registration of the capital increase in the commercial register, the share capital of the Company will increase to EUR 146,197,758.00 or 146,197,758 ordinary bearer shares respectively.

Evotec will be using the proceeds from the capital increase to accelerate its focused innovation and roll-up strategy in the outsourcing and external innovation drug discovery industry.

EN
09/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Evotec SE

Evotec SE: 1 director

A director at Evotec SE bought 20,000 shares at 5.475EUR and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Thomas J. Schiessle
  • Thomas J. Schiessle

Schwache Konjunktur verzögert weiterhin „Profitability Restart“ - Mone...

Q3/25-KPIs zeigen eine Umsatz- und EBITDA Margen-Verschlechterung (Umsatz -11% YoY auf € 164 Mio./Marge: -9,17 %; EPS € -0,24), doch sind diese durch Phasing-Effekte und Reset-Einsparungen überzeichnet. Die anhaltend schwache Nachfrage im Markt für frühe Arzneimittelforschung (D&PD) konnte das gut gelaufene Geschäft von Just-Evotec Biologics (JEB) nur teilweise ausgleichen. Zudem kämpft Evotec mit Unterauslastung. Hinzu kommen Kosten im Zusammenhang mit dem Anlaufen der JEB-Anlage im französisch...

Thomas J. Schiessle
  • Thomas J. Schiessle

Weak economic conditions continue to delay the 'Profitability Restart'...

Q3/25 KPIs show a decline in revenue and EBITDA margins (revenue -11% YoY to €164m / margin: -9.17%; EPS € -0.24), but these are exaggerated due to phasing effects and reset savings. The persistently weak demand in the early drug discovery (D&PD) market could only partially offset the well-performing business of Just-Evotec Biologics (JEB). Additionally, Evotec is struggling with underutilization. There are also costs associated with the start-up of the JEB facility in Toulouse, France, which is...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch